Optimizing efficacy of Amphotericin B through nanomodification.
The polyene antibiotic Amphotericin B (AMB) is one of the first therapeutic agents to be marketed commercially as nanosized formulations in which the drug is associated with lipids as liposomes or complexes. In this way, its renal toxicity is reduced and its therapeutic index improved. This review summarizes the particular properties of AMB which justify this type of formulation and the early work leading up to their development. The clinical results obtained in the treatment of fungal infections are reviewed and their activity against leishmaniasis is also evoked. Some newer formulations of AMB, based on both lipids and polymers are described. In particular, their potential by the oral and pulmonary routes are discussed. Finally, the development of targeted systems to deliver the drug to specific cells and tissues is considered.
Barratt
Gillian
G
UMR CNRS 8612, Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, Univ. Paris-Sud II, Faculté de Pharmacie, IFR 141, Châtenay-Malabry, France. gillian.barratt@u-psud.fr
Bretagne
Stéphane
S
D000666:Amphotericin B / Q000008:administration & dosage* / Q000737:chemistry*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D050997:Nanomedicine / Q000379:methods*; D049329:Nanostructures / Q000008:administration & dosage* / Q000737:chemistry* / Q000648:ultrastructure
D000935:Antifungal Agents; D004337:Drug Carriers; D000666:Amphotericin B